Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 82

Sort by

Sort Order Select

Journal Articles

Multi-center real world analysis of treatment outcomes of non-COVALENT btki, pirtobrutinib, in patients with COVALENT btki relapsed/refracdtory Mantle Cell Lymphoma

Blood (2025) 146 (Supplement 1): 5351.

https://doi.org/10.1182/blood-2025-5351

Published: 2025

Journal Articles

Rondecabtagene autoleucel, an autologous, dual-targeting CD19/CD20 CAR T-cell candidate manufactured from CD62L+ enriched T cells, achieves durable responses in patients with large B-cell lymphoma

Sarah Larson, Umar Farooq, Tahir Latif, Felix Mensah, Bradley Hunter, Stefan Ciurea, Nebu Koshy, Locke Bryan, Boyu Hu, William Clark, Hassaan Yasin, Yeonhee Kim, Greg Kaufman, Akil Merchant

Blood (2025) 146 (Supplement 1): 668.

https://doi.org/10.1182/blood-2025-668

Published: 2025

Journal Articles

Patterns of care and outcomes in patients with large B-cell lymphoma not treated with full-dose anthracycline regimens: Outcome analysis from the lymphoma epidemiology of outcomes (LEO) prospective cohort study

Blood (2025) 146 (Supplement 1): 6312.

https://doi.org/10.1182/blood-2025-6312

Published: 2025

Journal Articles

CD62L enrichment achieves robust expansion and memory phenotype post-infusion in patients with LBCL treated with rondecabtagene autoleucel, an autologous, dual-targeting CD19/CD20 CAR T-cell candidate

Akil Merchant, Ben Harris, Lora Zhao, Sahithi Cheemalamarri, Sobha Potluri, Tahir Latif, Umar Farooq, Sarah Larson

Blood (2025) 146 (Supplement 1): 501.

https://doi.org/10.1182/blood-2025-501

Published: 2025

Journal Articles

Sustained remissions beyond 4 years with epcoritamab monotherapy: Long term follow-up results from the pivotal EPCORE NHL-1 trial in patients with relapsed or refractory large B-cell lymphoma

Yasmin Karimi, Chan Cheah, Julie Vose, Michael Roost Clausen, David Cunningham, Umar Farooq, Tatyana Feldman, Herve Ghesquieres, Wojciech Jurczak, Kim Linton, Tycel Phillips, Won Seog Kim, Pegah Jafarinasabian, Barbara D'Angelo Månsson, Milan Geybels, Christian Eskelund, Martin Hutchings, Catherine Thieblemont

Blood (2025) 146 (Supplement 1): 5513.

https://doi.org/10.1182/blood-2025-5513

Published: 2025

Journal Articles

Outcomes in the 2nd decade following follicular lymphoma (FL) diagnosis: Long-term follow-up from the university of Iowa/Mayo Clinic SPORE molecular epidemiology resource (MER)

Blood (2025) 146 (Supplement 1): 1007.

https://doi.org/10.1182/blood-2025-1007

Published: 2025

Journal Articles

3-Year Update from the Epcore NHL-1 Trial: Epcoritamab Leads to Deep and Durable Responses in Relapsed or Refractory Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 4480.

https://doi.org/10.1182/blood-2024-198714

Published: 2024

Journal Articles

Phase I Study Results of UF-Kure19, a CAR-T Product Manufactured in Less Than 1 Day, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma

Changchun Deng, Paolo F. Caimi, Umar Farooq, Nethrie Idippily, Maria Florencia Giraudo, Jane S. Reese, Sarah Kleinsorge-Block, Daniel Caley, Ryan Stadel, Koen van Besien, Marcos de Lima, Arun Kumar Arunachalam, J. Joseph Melenhorst, David Wald

Blood (2024) 144 (Supplement 1): 94.

https://doi.org/10.1182/blood-2024-206596

Published: 2024

Journal Articles

Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with R-GemOx: A Multi-Center Retrospective Cohort Study

Blood (2024) 144 (Supplement 1): 3093.

https://doi.org/10.1182/blood-2024-208111

Published: 2024

Journal Articles

First Results of IMPT-314, an Autologous Bispecific CD19/CD20 Chimeric Antigen Receptor (CAR) in Enriched Naive and Central Memory T Cells, for the Treatment of Large B Cell Lymphoma (LBCL)

Sarah M. Larson, Umar Farooq, Boyu Hu, Tahir Latif, Felix A. Mensah, Deepthi Kolli, Giulia Parisi, Greg P. Kaufman, Jonathan E. Benjamin, Akil Merchant

Blood (2024) 144 (Supplement 1): 4824.

https://doi.org/10.1182/blood-2024-200697

Published: 2024

Journal Articles

Predictors of Early Safety Outcomes with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Christopher Strouse, Umar Farooq, Roni Shouval, Anusha Vallurupalli, Amy Moskop, Caron A. Jacobson, Frederick Locke, John H. Baird, Paolo Strati, Dilan A. Patel, Saurabh Dahiya, Michael T. Hemmer, Brad Du, Clare Spooner, Jenny J. Kim, Debbie L. Mirjah, Zhen-Huan Hu, Marcelo C. Pasquini, Yi Lin

Blood (2024) 144 (Supplement 1): 609.

https://doi.org/10.1182/blood-2024-207976

Published: 2024

Journal Articles

T-cell help in the tumor microenvironment enhances rituximab-mediated NK-cell ADCC

Jyoti Arora, Sabarish Ayyappan, Chaobo Yin, Brian J. Smith, Caitlin D. Lemke-Miltner, Zhaoming Wang, Umar Farooq, George J. Weiner

Blood (2024) 143 (18): 1816–1824.

https://doi.org/10.1182/blood.2023023370

Published: 2024

Includes: Supplemental data

Journal Articles

Autologous Stem Cell Transplant in Fit Patients with Late Relapsed Diffuse Large B-Cell Lymphoma That Responded to Salvage Chemotherapy

Aung M. Tun, Seth Maliske, Yucai Wang, David James Inwards, Thomas M. Habermann, Ivana Micallef, Luis Porrata, Jonas Paludo, J. C. Villasboas, Allison C. Rosenthal, Mohamed A. Kharfan-Dabaja, Stephen M Ansell, Grzegorz S. Nowakowski, Umar Farooq, Patrick B Johnston

Blood (2023) 142 (Supplement 1): 2216.

https://doi.org/10.1182/blood-2023-185002

Published: 2023

Journal Articles

Improved Overall Survival with Axicabtagene Ciloleucel Vs Standard of Care in Second-Line Large B-Cell Lymphoma Among the Elderly: A Subgroup Analysis of ZUMA-7

Blood (2023) 142 (Supplement 1): 1761.

https://doi.org/10.1182/blood-2023-173873

Published: 2023

Journal Articles

The Presence of Bulky Disease and/or Very High LDH Defines a High-Risk Subset of IPI 1-2 for Eligibility in Clinical Trials of Newly Diagnosed Aggressive B-Cell Lymphoma

Matthew J. Maurer, Arushi Khurana, Umar Farooq, Jason T. Romancik, Jonathan W. Friedberg, Izidore S. Lossos, Brad S. Kahl, Peter Martin, Dai Chihara, Andrew L. Feldman, Sergei Syrbu, David L Jaye, Elliot Cahn, Thomas M. Habermann, Brian K. Link, James R. Cerhan, Christopher R. Flowers, Loretta J. Nastoupil, Grzegorz S. Nowakowski

Blood (2023) 142 (Supplement 1): 4512.

https://doi.org/10.1182/blood-2023-187350

Published: 2023

Journal Articles

An International Multicohort Study of Conditional Survival and Cause of Death after Achieving Event-Free Survival at 24 Months in Patients with Mantle Cell Lymphoma

Blood (2023) 142 (Supplement 1): 1656.

https://doi.org/10.1182/blood-2023-182747

Published: 2023

Journal Articles

Clinical Outcomes of Patients Receiving 3 Versus 4 Doses of Methotrexate with Concomitant Anti-Thymocyte Globulin; A Single Center Experience

Kittika Poonsombudlert, Sarah L Mott, Brenda Miller, Hira Shaikh, Christopher Strouse, Jonathan Lochner, Umar Farooq, Margarida Magalhaes-Silverman

Blood (2023) 142 (Supplement 1): 2174.

https://doi.org/10.1182/blood-2023-181780

Published: 2023

Journal Articles

Mitigating the Risk of Cytokine Release Syndrome (CRS): Preliminary Results from a DLBCL Cohort of Epcore NHL-1

Blood (2023) 142 (Supplement 1): 1729.

https://doi.org/10.1182/blood-2023-180333

Published: 2023

Journal Articles

Overall Survival Following First and Second Relapse of DLBCL Treated with Therapies Including Autologous Transplant and CAR-T Cells: Results from the Lion Prospective Observational Registry

Greg Kirkpatrick, Jeffrey M. Switchenko, Melissa Kives, Katelin Baird, Kami J. Maddocks, Jason T. Romancik, Deborah M. Stephens, Harsh Shah, Javier Pinilla-Ibarz, Julio C Chavez, Matthew Matasar, Craig A. Portell, Michelle Churchman, Jonathon B. Cohen, Umar Farooq, Brian K. Link

Blood (2023) 142 (Supplement 1): 6325.

https://doi.org/10.1182/blood-2023-187198

Published: 2023

Journal Articles

Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma

Blood (2023) 141 (19): 2307–2315.

https://doi.org/10.1182/blood.2022018893

Published: 2023

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Multi-center real world analysis of treatment outcomes of non-COVALENT btki, pirtobrutinib, in patients with COVALENT btki relapsed/refracdtory Mantle Cell Lymphoma

Rondecabtagene autoleucel, an autologous, dual-targeting CD19/CD20 CAR T-cell candidate manufactured from CD62L+ enriched T cells, achieves durable responses in patients with large B-cell lymphoma

Patterns of care and outcomes in patients with large B-cell lymphoma not treated with full-dose anthracycline regimens: Outcome analysis from the lymphoma epidemiology of outcomes (LEO) prospective cohort study

CD62L enrichment achieves robust expansion and memory phenotype post-infusion in patients with LBCL treated with rondecabtagene autoleucel, an autologous, dual-targeting CD19/CD20 CAR T-cell candidate

Sustained remissions beyond 4 years with epcoritamab monotherapy: Long term follow-up results from the pivotal EPCORE NHL-1 trial in patients with relapsed or refractory large B-cell lymphoma

Outcomes in the 2nd decade following follicular lymphoma (FL) diagnosis: Long-term follow-up from the university of Iowa/Mayo Clinic SPORE molecular epidemiology resource (MER)

3-Year Update from the Epcore NHL-1 Trial: Epcoritamab Leads to Deep and Durable Responses in Relapsed or Refractory Large B-Cell Lymphoma

Phase I Study Results of UF-Kure19, a CAR-T Product Manufactured in Less Than 1 Day, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma

Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with R-GemOx: A Multi-Center Retrospective Cohort Study

First Results of IMPT-314, an Autologous Bispecific CD19/CD20 Chimeric Antigen Receptor (CAR) in Enriched Naive and Central Memory T Cells, for the Treatment of Large B Cell Lymphoma (LBCL)

Predictors of Early Safety Outcomes with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

T-cell help in the tumor microenvironment enhances rituximab-mediated NK-cell ADCC

Autologous Stem Cell Transplant in Fit Patients with Late Relapsed Diffuse Large B-Cell Lymphoma That Responded to Salvage Chemotherapy

Improved Overall Survival with Axicabtagene Ciloleucel Vs Standard of Care in Second-Line Large B-Cell Lymphoma Among the Elderly: A Subgroup Analysis of ZUMA-7

The Presence of Bulky Disease and/or Very High LDH Defines a High-Risk Subset of IPI 1-2 for Eligibility in Clinical Trials of Newly Diagnosed Aggressive B-Cell Lymphoma

An International Multicohort Study of Conditional Survival and Cause of Death after Achieving Event-Free Survival at 24 Months in Patients with Mantle Cell Lymphoma

Clinical Outcomes of Patients Receiving 3 Versus 4 Doses of Methotrexate with Concomitant Anti-Thymocyte Globulin; A Single Center Experience

Mitigating the Risk of Cytokine Release Syndrome (CRS): Preliminary Results from a DLBCL Cohort of Epcore NHL-1

Overall Survival Following First and Second Relapse of DLBCL Treated with Therapies Including Autologous Transplant and CAR-T Cells: Results from the Lion Prospective Observational Registry

Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only